Xeptiva's
|
FOR THE TREATMENT OF PAIN ASSOCIATED WITH CANINE OSTEOARTHTRITIS
|
The objective of the study is to validate the development of Xep01, for the treatment of chronic pain associated with osteoarthritis in dogs. |
The treatment consist of the Xep01 vaccine that stimulates the production of antibodies that decrease pain and inflammation in vaccinated dogs. |
All costs associated with the study, such as diagnosis, laboratory analysis during the trial, and clinical follow-up, will be covered by the sponsoring company. |
Previous animal studies have demonstrated that the Xep01 vaccine is safe, well-tolerated, and effective for treating pain associated with canine osteoarthritis. The vaccine has been shown to provide long-lasting pain relief, improve mobility and anial well-being, and reduce the need for pain medication in dogs with advanced osteoarthritis. Most recently, a safety pilot trial in healthy dogs confirmed that vaccination with Xep01 does not cause any significant local or systemic adverse effects. Overall, the evidence from these studies supports the safety and efficacy of the Xep01 vaccine for managing pain and improving outcomes in canine osteoarthritis patients. |